Chembio Diagnostic Inc - Company Profile
Powered by 
All the data and insights you need on Chembio Diagnostic Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Chembio Diagnostic Inc Strategy Report
- Understand Chembio Diagnostic Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chembio Diagnostic Inc (Chembio) develops, manufactures, markets and licenses point-of-care diagnostic (POCs) tests for the detection of infectious diseases including COVID-19, sexually transmitted disease, and fever and tropical disease. The company offers products to prevent the spread of infectious diseases with solutions includes Dual Path Platform (DPP). Its DPP technology is used to treat infectious diseases such as HIV, Ebola, syphilis, Zika, malaria and febrile illness. Chembio also offers veterinary diagnostics. The company offers products to medical laboratories and hospitals, governmental, non-governmental organizations, and public health entities, medical professionals and retailers. The company distributes products through a network of distributors worldwide. Chembio is headquartered in Hauppauge, New York, the US.
Headquarters
United States of America
Address
3661 Horseblock Road, Medford, New York, 11763
Website
chembio.com
Telephone
1 631 9241135
No of Employees
188
Industry
Medical Equipment
Revenue (2022)
$49.5M
Chembio Diagnostic Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Products | DPP |
| Dual Path Platform | SAMPLETAINER |
| Human Diagnostic | STAT-PAK |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In July, the company acquired the FastPack diagnostics business from Qualigen Therapeutics. |
| 2023 | Contracts/Agreements | In January, the company and Biosynex entered into a definitive merger agreement. |
| 2022 | Contracts/Agreements | In October, the company was awarded a US$3.2 billion contract for the development and clinical validation of a rapid point-of-care (POC) diagnostic test for syphilis from the Centers for Disease Control and Prevention (CDC). |
Competitor Comparison
| Key Parameters | Chembio Diagnostic Inc | Abbott Laboratories | OraSure Technologies Inc | Universal Biosensors Inc | bioLytical Laboratories Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Australia | Canada |
| City | Medford | Abbott Park | Bethlehem | Melbourne | Richmond |
| State/Province | New York | Illinois | Pennsylvania | Victoria | British Columbia |
| No. of Employees | 188 | 114,000 | 638 | 97 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Katherine L. Davis | Chairman | Executive Board | 2014 | 65 |
| Richard L. Eberly | Director; Chief Executive Officer; President | Executive Board | 2020 | 62 |
| Larry Steenvoorden | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | - |
| Javan Esfandiari | Chief Operating Officer; Chief Science and Technology Officer; Executive Vice President - Research and Development | Senior Management | 2015 | 56 |
| Paul J. Angelico | Chief Operating Officer; Executive Vice President | Senior Management | - | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer